Natural Product Target Network Reveals Potential for Cancer Combination Therapies

Abstract

A body of research demonstrates examples of in vitro and in vivo synergy between natural products and anti-neoplastic drugs for some cancers. However, the underlying biological mechanisms are still elusive. To better understand biological entities targeted by natural products and therefore provide rational evidence for future novel combination therapies for cancer treatment, we assess the targetable space of natural products using public domain compound-target information. When considering pathways from the Reactome database targeted by natural products, we found an increase in coverage of 61% (725 pathways), relative to pathways covered by FDA approved cancer drugs collected in the Cancer Targetome, a resource for evidence-based drug-target interactions. Not only is the coverage of pathways targeted by compounds increased when we include natural products, but coverage of targets within those pathways is also increased. Furthermore, we examined the distribution of cancer driver genes across pathways to assess relevance of natural products to critical cancer therapeutic space. We found 24 pathways enriched for cancer drivers that had no available cancer drug interactions at a potentially clinically relevant binding affinity threshold of < 100nM that had at least one natural product interaction at that same binding threshold. Assessment of network context highlighted the fact that natural products show target family groupings both distinct from and in common with cancer drugs, strengthening the complementary potential for natural products in the cancer therapeutic space. In conclusion, our study provides a foundation for developing novel cancer treatment with the combination of drugs and natural products.

Chelerythrine Chloride Downregulates β-Catenin and Inhibits Stem Cell Properties of Non-Small Cell Lung Carcinoma

“…A recent study revealed the potential synergistic effect of increasing pathways targeting coverage in combinatorial regimens consisting of phytochemical compounds and chemotherapy [56]. Phytochemical compounds also have the potential to alleviate toxicity induced by chemotherapy, further justifying their usage along with the traditional treatment modalities [55].…”

2α-Hydroxyeudesma-4,11(13)-Dien-8β,12-Olide Isolated from Inula britannica Induces Apoptosis in Diffuse Large B-cell Lymphoma Cells

“…However, only a slight effect was observed with 50 and 100 µM. As cancer is a multifactorial disease, it requires treatment with compounds able to target multiple intracellular molecules [33,34]. Traditional medicines and natural products are used as direct sources of natural agents that harbor multiple therapeutic effects [24,35].…”

"Desert Chemotypes": The Potential of Desert Plants-Derived Metabolome to Become a Sustainable Resource for Drug Leads

“…For example, the combined treatment of A. graveolens fraction, sensitized cancer cells in vitro and cisplatin/etoposide/doxorubicin through the induction of ROS and caspase-3-dependent apoptosis 44 . The mode of action of a combination of drugs is different than that of the same drugs acting individually; hence isolating a single component may lose its effectiveness 79,80 .The versatility of a natural product target network, for example, suggests that plant extracts can serve as good candidates for cancer combination therapies 81 . Schweinf.…”